Joseph A Carcillo1, Bradley Podd, Rajesh Aneja, Scott L Weiss, Mark W Hall, Timothy T Cornell, Thomas P Shanley, Lesley A Doughty, Trung C Nguyen. 1. 1Department of Critical Care Medicine and Pediatrics, University of Pittsburgh, Pittsburgh, PA. 2Department of Anesthesiology and Critical Care, University of Pennsylvania, Philadelphia, PA. 3Department of Pediatrics, Nationwide Children's Hospital, Columbus, OH. 4Department of Pediatrics, University of Michigan, Ann Arbor, MI. 5Department of Pediatrics, Cincinnati Children's Hospital, Cincinnati, OH. 6Department of Pediatrics, Texas Children's Hospital, Houston, TX.
Abstract
OBJECTIVE: To describe the pathophysiology associated with multiple organ dysfunction syndrome in children. DATA SOURCES: Literature review, research data, and expert opinion. STUDY SELECTION: Not applicable. DATA EXTRACTION: Moderated by an experienced expert from the field, pathophysiologic processes associated with multiple organ dysfunction syndrome in children were described, discussed, and debated with a focus on identifying knowledge gaps and research priorities. DATA SYNTHESIS: Summary of presentations and discussion supported and supplemented by relevant literature. CONCLUSIONS: Experiment modeling suggests that persistent macrophage activation may be a pathophysiologic basis for multiple organ dysfunction syndrome. Children with multiple organ dysfunction syndrome have 1) reduced cytochrome P450 metabolism inversely proportional to inflammation; 2) increased circulating damage-associated molecular pattern molecules from injured tissues; 3) increased circulating pathogen-associated molecular pattern molecules from infection or endogenous microbiome; and 4) cytokine-driven epithelial, endothelial, mitochondrial, and immune cell dysfunction. Cytochrome P450s metabolize endogenous compounds and xenobiotics, many of which ameliorate inflammation, whereas damage-associated molecular pattern molecules and pathogen-associated molecular pattern molecules alone and together amplify the cytokine production leading to the inflammatory multiple organ dysfunction syndrome response. Genetic and environmental factors can impede inflammation resolution in children with a spectrum of multiple organ dysfunction syndrome pathobiology phenotypes. Thrombocytopenia-associated multiple organ dysfunction syndrome patients have extensive endothelial activation and thrombotic microangiopathy with associated oligogenic deficiencies in inhibitory complement and a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13. Sequential multiple organ dysfunction syndrome patients have soluble Fas ligand-Fas-mediated hepatic failure with associated oligogenic deficiencies in perforin and granzyme signaling. Immunoparalysis-associated multiple organ dysfunction syndrome patients have impaired ability to resolve infection and have associated environmental causes of lymphocyte apoptosis. These inflammation phenotypes can lead to macrophage activation syndrome. Resolution of multiple organ dysfunction syndrome requires elimination of the source of inflammation. Full recovery of organ functions is noted 6-18 weeks later when epithelial, endothelial, mitochondrial, and immune cell regeneration and reprogramming is completed.
OBJECTIVE: To describe the pathophysiology associated with multiple organ dysfunction syndrome in children. DATA SOURCES: Literature review, research data, and expert opinion. STUDY SELECTION: Not applicable. DATA EXTRACTION: Moderated by an experienced expert from the field, pathophysiologic processes associated with multiple organ dysfunction syndrome in children were described, discussed, and debated with a focus on identifying knowledge gaps and research priorities. DATA SYNTHESIS: Summary of presentations and discussion supported and supplemented by relevant literature. CONCLUSIONS: Experiment modeling suggests that persistent macrophage activation may be a pathophysiologic basis for multiple organ dysfunction syndrome. Children with multiple organ dysfunction syndrome have 1) reduced cytochrome P450 metabolism inversely proportional to inflammation; 2) increased circulating damage-associated molecular pattern molecules from injured tissues; 3) increased circulating pathogen-associated molecular pattern molecules from infection or endogenous microbiome; and 4) cytokine-driven epithelial, endothelial, mitochondrial, and immune cell dysfunction. Cytochrome P450s metabolize endogenous compounds and xenobiotics, many of which ameliorate inflammation, whereas damage-associated molecular pattern molecules and pathogen-associated molecular pattern molecules alone and together amplify the cytokine production leading to the inflammatory multiple organ dysfunction syndrome response. Genetic and environmental factors can impede inflammation resolution in children with a spectrum of multiple organ dysfunction syndrome pathobiology phenotypes. Thrombocytopenia-associated multiple organ dysfunction syndromepatients have extensive endothelial activation and thrombotic microangiopathy with associated oligogenic deficiencies in inhibitory complement and a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13. Sequential multiple organ dysfunction syndromepatients have soluble Fas ligand-Fas-mediated hepatic failure with associated oligogenic deficiencies in perforin and granzyme signaling. Immunoparalysis-associated multiple organ dysfunction syndromepatients have impaired ability to resolve infection and have associated environmental causes of lymphocyte apoptosis. These inflammation phenotypes can lead to macrophage activation syndrome. Resolution of multiple organ dysfunction syndrome requires elimination of the source of inflammation. Full recovery of organ functions is noted 6-18 weeks later when epithelial, endothelial, mitochondrial, and immune cell regeneration and reprogramming is completed.
Authors: Anne-Laure Lapeyraque; Michal Malina; Véronique Fremeaux-Bacchi; Tobias Boppel; Michael Kirschfink; Mehdi Oualha; François Proulx; Marie-José Clermont; Françoise Le Deist; Patrick Niaudet; Franz Schaefer Journal: N Engl J Med Date: 2011-05-25 Impact factor: 91.245
Authors: S Hashimoto; A Kobayashi; K Kooguchi; Y Kitamura; H Onodera; H Nakajima Journal: Am J Respir Crit Care Med Date: 2000-01 Impact factor: 21.405
Authors: Daniel W Lee; Rebecca Gardner; David L Porter; Chrystal U Louis; Nabil Ahmed; Michael Jensen; Stephan A Grupp; Crystal L Mackall Journal: Blood Date: 2014-05-29 Impact factor: 22.113
Authors: Jennifer A Muszynski; Ryan Nofziger; Kristin Greathouse; Jyotsna Nateri; Lisa Hanson-Huber; Lisa Steele; Kathleen Nicol; Jonathan I Groner; Gail E Besner; Corey Raffel; Susan Geyer; Osama El-Assal; Mark W Hall Journal: Shock Date: 2014-10 Impact factor: 3.454
Authors: Howard Lin; Brooks P Scull; Baruch R Goldberg; Harshal A Abhyankar; Olive E Eckstein; Daniel J Zinn; Joseph Lubega; Jennifer Agrusa; Nader El Mallawaney; Nitya Gulati; Lisa Forbes; Ivan Chinn; Rikhia Chakraborty; Jessica Velasquez; Jordana Goldman; Dalia Bashir; Fong Lam; Eyal Muscal; Michael M Henry; Jay N Greenberg; Stephan Ladisch; Michelle L Hermiston; Lauren K Meyer; Michael Jeng; Ahmed Naqvi; Kenneth McClain; Trung Nguyen; Hector Wong; Tsz-Kwong Man; Michael B Jordan; Carl E Allen Journal: Blood Adv Date: 2021-09-14
Authors: Mihir R Atreya; Natalie Z Cvijanovich; Julie C Fitzgerald; Scott L Weiss; Michael T Bigham; Parag N Jain; Adam J Schwarz; Riad Lutfi; Jeffrey Nowak; Geoffrey L Allen; Neal J Thomas; Jocelyn R Grunwell; Torrey Baines; Michael Quasney; Bereketeab Haileselassie; Christopher J Lindsell; Matthew N Alder; Hector R Wong Journal: Crit Care Date: 2022-07-11 Impact factor: 19.334
Authors: Joseph A Carcillo; Robert A Berg; David Wessel; Murray Pollack; Kathleen Meert; Mark Hall; Christopher Newth; John C Lin; Allan Doctor; Tom Shanley; Tim Cornell; Rick E Harrison; Athena F Zuppa; Ron W Reeder; Russell Banks; John A Kellum; Richard Holubkov; Daniel A Notterman; J Michael Dean Journal: Pediatr Crit Care Med Date: 2019-12 Impact factor: 3.624
Authors: James D Fortenberry; Trung Nguyen; Jocelyn R Grunwell; Rajesh K Aneja; Derek Wheeler; Mark Hall; Geoffrey Fleming; Rod Tarrago; Sandra Buttram; Heidi Dalton; Yong Han; Kirk A Easley; Andrea Knezevic; Tian Dai; Matthew Paden; Joseph A Carcillo Journal: Crit Care Med Date: 2019-03 Impact factor: 7.598
Authors: Monique M Gardner; Matthew P Kirschen; Hector R Wong; Daniel J McKeone; E Scott Halstead; Jill M Thompson; Adam S Himebauch; Alexis A Topjian; Nadir Yehya Journal: Resuscitation Date: 2021-12-03 Impact factor: 5.262
Authors: Jordana Goldman; Moreshwar S Desai; Kenneth L McClain; M Hossein Tcharmtchi; Curtis E Kennedy; Kathleen Thompson; Fong Lam; Dalia A Bashir; Ivan K Chinn; Baruch R Goldberg; Carl E Allen; Trung C Nguyen Journal: Pediatr Crit Care Med Date: 2018-10 Impact factor: 3.971
Authors: Jennifer K Workman; David K Bailly; Ron W Reeder; Heidi J Dalton; Robert A Berg; Thomas P Shanley; Christopher J L Newth; Murray M Pollack; David Wessel; Joseph Carcillo; Rick Harrison; J Michael Dean; Kathleen L Meert Journal: ASAIO J Date: 2020 Nov/Dec Impact factor: 3.826